Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC formulary coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    BlueCross Total Value 2026 Formulary — Drug List and Requirements/Limits

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the BlueCross Total Value 2026 prescription drug formulary and rules for coverage, prior authorization, quantity limits, step therapy, and exceptions for plan members and prescribers.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Value 2026 Formulary — Drug List
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization when a drug is marked PA (or PA NSO) and submit supporting documentation to secure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    04/01/2026Formulary effective/last updated date
    MonthlyFormulary updates
    MultipleDrugs with PA
    MultipleDrugs with QL
    6Drug tiers
    26218Formulary ID

    Coverage Criteria

    General coverage criteria

    Covered when ALL of the following conditions are met:

    Formulary coverage basic conditions: Drug is listed on the BlueCross Total Value formulary AND the prescription is filled at a BlueCross Total Value network pharmacy AND the drug is medically necessary for the member.

    Based on formulary definition and coverage restrictions

    Utilization control compliance: All applicable plan utilization controls are satisfied for the requested drug (e.g., required Prior Authorization obtained; Quantity Limits not exceeded; Step Therapy requirements met).

    See Requirements/Limits flags (PA, QL, ST, NDS) in formulary; failure to obtain PA or exceed QL may result in denial.

    Exception and transition provisions: When standard coverage conditions are not met, coverage may still be provided if an approved exception exists OR a temporary transition supply applies (e.g., temporary 30-day supply while an exception or coverage determination is pending; 31-day LTC emergency supply where applicable).
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Value 2026 Formulary — Drug List
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must obtain prior authorization when a drug is marked PA (or PA NSO) and submit supporting documentation to secure coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Requirements/Limits CodesProvider Actions, Prior Authorization & Step TherapyInitial Therapy Criteria / Selected AgentsStep Therapy RulesQuantity Limits (QL) — Per-Product ExamplesSite of Care / Dispensing RulesDefinitions and AbbreviationsBackgroundBiosimilar Substitution
    30 days / 31 days

    Members may request formulary or restriction exceptions; decisions: standard 72 hours, expedited 24 hours.

    Per-drug coverage flags and limits

    Coverage status and any utilization controls are displayed for each product in the formulary table; a listed product may be covered subject to the specific flags shown.

    Formulary table entry components: Each drug row includes: drug name and strength/formulation; Drug Tier; and Requirements/Limits flags such as PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy) and NSO annotations.

    Follow the specified flags for coverage and required documentation.

    Formulary listing with requirements/limits

    Formulary listing entries include tiering and utilization controls; follow the Requirements/Limits column for coverage details.

    General formulary listing: Drugs are assigned a Drug Tier and may have Requirements/Limits (for example: PA, QL) indicated next to the product name; coverage is subject to those indicated requirements.

    Examples in the formulary: GENOTROPIN products listed with PA; ISTURISA formulations listed with QL and PA.

    Drugs that are withdrawn from sale by the manufacturer or that the FDA withdraws for safety or effectiveness reasons may be immediately removed from the formulary and not covered. When other changes (for example, adding a generic or biosimilar, applying new restrictions, or moving a drug to a different cost-sharing tier) are made, the plan will generally provide at least 30 days notice to affected members or supply a one-time 30-day refill with notice when a member requests a refill. Members or prescribers may request an exception to continue coverage where medically justified.

    The provided extract is a formulary table showing drug entries with tier assignments and Requirements/Limits annotations (e.g., QL, PA, ST, NSO). There are no explicit clinical exclusion statements or standalone 'not covered' listings in these chunks; exclusions are represented indirectly through requirement flags rather than clinical exclusion text.

    Within the excerpt, coverage is expressed via formulary table entries and Requirements/Limits flags (such as QL and PA). The text does not contain explicit statements that any listed product is categorically not covered; instead, restrictions are implemented through the table flags and quantity limits.

    This extract consists of drug list table rows with tiering and Requirements/Limits annotations. It does not include explicit exclusion language that would remove coverage for specific patient populations or indications; any limitations are indicated by table flags (e.g., PA, QL) rather than standalone exclusion statements.

    Some formulary entries are restricted to a specific manufacturer's labeled products (for example, listings that state 'Boehringer Ingelheim labeled products only' or 'AbbVie labeled products only'). These annotations limit coverage to the named manufacturer's labeled presentations and exclude other manufacturers' versions for that listing.

    The excerpted table uses Requirements/Limits annotations to indicate utilization controls but does not include any explicit determinations that items are not medically necessary. No 'not medically necessary' rulings are present in these chunks.

    In this portion of the formulary excerpt, coverage status is shown via tier assignments and requirement flags. There are no statements in this excerpt identifying items as not medically necessary or otherwise excluding coverage on that clinical basis.

    The extract lists drug names, tiers, and Requirements/Limits flags (e.g., PA for GENOTROPIN) but does not include any explicit text designating products as not medically necessary. No items in this chunk are labeled with that determination.

    Coding and Requirements/Limits Codes

    Requirements/Limits codesmixed
    PAPrior Authorization
    QLQuantity Limits
    NDSNon-Extended Day Supply
    STStep Therapy
    B/DDrug that may be covered under Medicare Part B or Medicare Part D, depending on the indication, where and how the drug was administered and by whom. The plan must first conduct a review to determine the correct coverage (B or D).
    No procedure/diagnosis codes presentmixed
    N/ANo CPT/HCPCS/ICD-10 or NDC codes listed in these chunks; only drug names, strengths, tiers and requirement annotations are present.
    Quantity limit codes and examplesmixed
    QL(60 EA per 30 days)Quantity limit example (multiple products listed with this QL)
    QL(148 EA per 365 days)Quantity limit example for ELIQUIS STARTER PACK (listed as 148 EA per 365 days in brief)
    QL(84 EA per 28 days)Quantity limit example for ELIQUIS CAPSULE SPRINKLE 0.15MG (example QL)
    QL(140 EA per 28 days)Quantity limit example (pack variants)
    QL(420 EA per 28 days)Quantity limit example (pack variants)
    QL(560 EA per 28 days)Quantity limit example (ELIQUIS tablet soluble pack example)
    QL(60 EA per 30 days)Quantity limit example for ELIQUIS TABLET 2.5MG / other products
    QL(90 EA per 30 days)Quantity limit example for ELIQUIS TABLET 5MG / other products
    QL(102 EA per 365 days)Quantity limit example for XARELTO STARTER PACK (example in brief)
    QL(600 ML per 30 days)Quantity limit example for XARELTO SUSPENSION RECONSTITUTED 1MG/ML
    1–10 of 16
    1/2
    Quantity limits (examples)mixed
    QL(60 EA per 30 days)Quantity limit of 60 each per 30 days for atomoxetine hydrochloride capsule 10mg
    QL(30 EA per 30 days)Quantity limit of 30 each per 30 days for atomoxetine capsule various strengths
    QL(90 EA per 30 days)Quantity limit of 90 each per 30 days for methylphenidate hydrochloride tablet (various strengths)
    PA and QL flagsmixed
    PAPrior authorization required (flag shown for multiple products)
    QL(56 EA per 365 days)Quantity limit example for therapy pack (AUSTEDO XR patient titration kit)
    QL(30 EA per 30 days)Quantity limit example for AUSTEDO XR extended release tablet
    QL(120 EA per 30 days)Quantity limit example for immediate-release AUSTEDO
    Benefit/Distribution flagsmixed
    B/DBenefit/Distribution flag shown for some injectable nutrition products (indicates may be covered under Medicare Part B or Part D depending on indication/administration)
    Step therapy codesmixed
    STStep therapy flag (example: diclofenac sodium gel 3% marked with ST)
    Formulary identifiersmixed
    Formulary ID: 26218Formulary identifier
    inv-22: Quantity limits examples — assorted sample QL formats
    Example formatsQL(30 EA per 90 days); QL(60 EA per 30 days); QL(1000 GM per 30 days); QL(4 EA per 28 days)
    Units and periodEA = each (count), GM = grams, ML = milliliters; periods shown as per 28/30/90/365 days
    Combined flagsQuantity limits often appear with other flags (e.g., QL(...); PA or QL(...); ST)
    inv-23: Example quantity limits — QL examples across document
    Common QL examplesQL(30 EA per 30 days); QL(2 ML per 28 days); QL(60 EA per 30 days); QL(450 ML per 30 days); QL(84 EA per 180 days)
    Therapy-pack and kit formatsSome therapy packs use annual QL (e.g., QL(56 EA per 365 days)) or per-pack QL distinctions
    B/D annotation with QLCertain QL entries include B/D designation indicating potential Part B/Part D review (e.g., aprepitant entries)
    inv-24: Quantity Limits examples — additional examples
    Mixed QL rangesQL(60 EA per 30 days); QL(120 EA per 365 days); QL(28 EA per 28 days)
    Cancer/oncology packsMany oncology products list QL per 30 days or per 365 days depending on pack size
    PA + QL occurrencesHigh-cost agents frequently pair QL with PA (e.g., SCEMBLIX shows QL values and PA NSO)
    inv-25: Quantity limits examples — multiple QL example values
    Assorted example values30 EA per 30 days; 60 EA per 30 days; 540 ML per 30 days; 560 EA per 365 days; 336 EA per 365 days
    Dose-form specific QLLiquid formulations commonly use ML (e.g., 540 ML per 30 days) while solids use EA
    Therapy-pack distinctionsTherapy packs may have separate QL for starter/titration pack vs. maintenance pack
    inv-26: Common Quantity Limits — common QL patterns observed
    Most frequent QLsQL(30 EA per 30 days); QL(60 EA per 30 days); QL(180 EA per 30 days); QL(960 ML per 30 days); QL(2 ML per 28 days)
    Monthly vs annual limitsSome products use per-30-day limits; others specify per-365-day limits for multi-dose therapy packs
    Extended-supply exceptionsNDS annotation indicates non-extended day supply where extended fills aren't permitted alongside QL
    inv-27: Quantity limits examples — exact QL values shown per drug
    Per-drug exact QL examplesExact QLs shown per drug (e.g., QL(60 EA per 30 days); QL(600 ML per 30 days))
    PA pairing notedSome exact QL entries include PA (e.g., QL(30 EA per 30 days); PA) for injectables and specialty agents
    Starter/pack variationsCertain products list different QL for starter packs versus regular pack (e.g., ELIQUIS starter pack vs regular)
    inv-28: ISTURISA quantity limits — 1mg and 5mg examples
    ISTURISA 1mg QLQL(240 EA per 30 days)
    ISTURISA 5mg QLQL(360 EA per 30 days)
    PA statusBoth ISTURISA strengths are listed with PA in the Requirements/Limits field
    inv-29: ESTRING quantity limit — example QL(1 EA per 90 days)
    ESTRING ring QLQL(1 EA per 90 days)
    Formulation notedESTRING RING 7.5MCG/24HR appears with the 1-per-90-day limit in the Hormonal Agents section
    Refer to introIntroduction pages define QL format and period (see introduction) for interpretation
    inv-30: OSP HENA (OSPHENA) quantity limit — QL(30 EA per 30 days)
    OSPHENA tablet QLQL(30 EA per 30 days)
    OSPHENA strengthOSPHENA TABLET 60MG listed with 30 each per 30 days
    ContextOSPHENA appears in Progestins/Hormonal Agents section with standard monthly QL
    inv-31: DEPO-SUBQ PROVERA 104 quantity limit — QL(0.65 ML per 90 days)
    DEPO‑SUBQ PROVERA 104 QLQL(0.65 ML per 90 days)
    Dose/formulationDEPO‑SUBQ PROVERA 104 INJECTION 104MG/0.65ML is limited to 0.65 mL per 90 days
    Related progestin limitmedroxyprogesterone acetate injection (150mg/mL) listed with QL(1 ML per 90 days) nearby
    inv-32: medroxyprogesterone acetate injection quantity limit — QL(1 ML per 90 days)
    Medroxyprogesterone injection QLQL(1 ML per 90 days)
    Formulation referencedmedroxyprogesterone acetate injection 150mg/mL appears with 1 mL per 90 days limit
    ConsistencyMatches nearby DEPO‑SUBQ PROVERA 104 entries that use ML per 90 days
    inv-33: Quantity limits examples — varied QL formats across document
    Assorted QL formatsExamples include QL(0.65 ML per 90 days); QL(1 EA per 28 days); QL(30 EA per 30 days); QL(104 ML per 365 days); QL(3 ML per 84 days); QL(60 ML per 30 days)
    Range of periodsLimits appear across periods (28 days, 30 days, 84 days, 365 days) depending on product and pack
    Injection/liquid conventionsInjectable biologics and liquids typically express limits in ML per period
    inv-34: Prior authorization requirement (definition-level) — PA required for certain drugs
    PA definitionPrior Authorization: BlueCross Total Value requires you or your prescriber to get prior authorization for certain drugs; coverage may be denied without approval
    PA flaggingThe Requirements/Limits column uses 'PA' and 'PA NSO' to indicate where prior authorization is required
    Provider actionPrescribers must submit PA requests following the plan's PA process; introduction pages provide PA submission details

    Provider Actions, Prior Authorization & Step Therapy

    Prior Authorization

    Obtain prior authorization before dispensing PA‑listed drugs

    Prescribers must obtain prior authorization (PA) from BlueCross Total Value before filling prescriptions for drugs annotated with PA or PA NSO in the formulary; without prior approval the plan may not cover the drug.

    • PA is required for coverage of products marked 'PA' or 'PA NSO'.
    • Examples include GENOTROPIN, INCRELEX, ISTURISA and many specialty biologics.
    Prior Authorization

    Follow Requirements/Limits key (PA, QL, NDS, ST) on submissions

    Follow the Requirements/Limits key when submitting requests: identify PA, QL, NDS and ST flags on the formulary entry and ensure supporting documentation addresses those specific requirements.

    • Use the Requirements/Limits key (PA, QL, NDS, ST, B/D) to determine required controls for each drug.
    • Supply documentation consistent with the flagged requirements when submitting PA or exception requests.
    Prior Authorization

    Submit PA for specialty/anticonvulsant products marked PA NSO

    Prior authorization is required for numerous specialty and anticonvulsant products designated 'PA NSO' — submit PA requests for those formulations per the formulary.

    • Examples of PA NSO products: BRIVIACT (solution and tablets), EPIDIOLEX (solution), DIACOMIT (capsule/packet), VIGAFYDE, ZTALMY.
    • PA NSO denotes prior authorization is required as indicated in the formulary introduction.
    Prior Authorization

    Request PA for selected high‑tier and specialty drugs

    Many high‑tier and specialty agents are marked 'PA' with quantity limits; prescribers must request prior authorization and document medical necessity for coverage.

    • Examples include AIMOVIG, EMGALITY, QULIPTA, NURTEC and select oncology/specialty agents.
    • Check respective QL entries (e.g., AIMOVIG QL per 28 days) when preparing PA submissions.
    Prior Authorization

    PA required for many specialty and oncology agents

    Numerous specialty and oncology agents require prior authorization (PA NSO); providers must submit PA requests following the plan’s PA process and refer to introduction pages for details.

    • PA NSO appears on many oncology and specialty entries — absence of PA may lead to denial.
    • Refer to formulary introduction pages for PA submission instructions and symbol definitions.
    Prior Authorization

    Submit PA for flagged formulations (PA / PA NSO)

    If a product is labeled 'PA' or 'PA NSO' for a specific formulation, providers must submit prior authorization for that formulation to obtain coverage.

    • Several listed formulations include the 'PA' annotation — submission must reference the exact formulation shown in the formulary.
    • Check the Requirements/Limits field on the drug row to identify PA applicability for the specific NDC/formulation.
    Prior Authorization

    Check formulary rows for PA annotations and request authorization

    Prior authorization is applied to many listed products; verify the formulary row for PA annotation and submit authorization requests before dispensing.

    • Examples of PA annotations include VYJUVEK GEL and diabetes specialty products (MOUNJARO, OZEMPIC).
    • Follow PA and QL guidance shown on the formulary for those products.
    Prior Authorization

    Obtain PA for listed PA‑designated supportive care and injection products

    Drugs designated 'PA' in the Requirements/Limits column (for example eltrombopag, NEULASTA, PROCRIT, RETACRIT, UDENYCA) require prior authorization prior to coverage.

    • Submit PA for colony‑stimulating factors, ESAs and related high‑cost supportive care injections listed as PA.
    • Claims submitted without required PA for these products may be denied.
    Prior Authorization

    Provide PA and QL justification for selected specialty/restricted drugs

    Certain specialty or restricted drugs are subject to prior authorization and quantity limits; prescribers must supply PA documentation referencing applicable QL values.

    • Examples: metyrosine = PA; PRALUENT and REPATHA have QL and PA requirements.
    • Include clinical justification and requested quantity relative to the stated QL when submitting PA.
    Prior Authorization

    Request PA for selected high‑tier agents and address ST where shown

    Multiple high‑tier products (e.g., AUSTEDO XR, INGREZZA, OTEZLA and many MS agents) carry PA flags; prescribers must request authorization and document indication and prior therapies where relevant.

    • Therapies flagged PA often also have QLs — include dose and duration details in PA requests.
    • For products with ST flags, ensure step‑therapy requirements are addressed or an exception is requested.
    Prior Authorization

    Obtain PA for multiple PA‑designated products to ensure coverage

    Several products across the formulary are designated 'PA' — providers must obtain prior authorization before dispensing to avoid claim denial.

    • Examples include deferasirox formulations, JYNARQUE (tolvaptan), RELISTOR, LIVMARLI and EVRYSDI.
    • Verify QL values and include them in the PA request as applicable.
    Prior Authorization

    Submit PA (and document QL) for growth hormone and related agents

    Growth hormone products and related agents (GENOTROPIN, INCRELEX, ISTURISA) are listed with PA (and QL for ISTURISA) — prescribers must submit a PA request that documents indication and quantity.

    • ISTURISA has explicit QLs (240 EA per 30 days for 1mg; 360 EA per 30 days for 5mg) and requires PA.
    • GENOTROPIN and INCRELEX are marked PA — include clinical rationale in the PA submission.
    Prior Authorization

    Follow PA process for PA and PA NSO‑flagged biologic/specialty drugs

    Many listed drugs are subject to prior authorization (PA) and PA NSO annotations; providers must follow the PA process for these products to secure coverage.

    • Biologic agents such as ENBREL, HUMIRA formulations and infliximab are examples requiring PA.
    • Check for manufacturer‑labeled or starter‑pack restrictions shown with PA entries.
    Prior Authorization

    Submit PA and follow manufacturer/label restrictions for biologics

    Many biologic and other specialty biologic agents (ENBREL, HUMIRA, infliximab and others) require prior authorization; submit PA requests and respect any manufacturer‑label or starter pack restrictions.

    • HUMIRA listings may be limited to AbbVie labeled products only — include product specificity in PA requests.
    • Starter pack QLs and PA requirements must be honored to avoid denials.
    Step Therapy

    Document trial and failure of first‑line therapy for Step Therapy

    Step therapy requires trying specified alternative drugs first; if the initial drug fails, document failure and submit for coverage of the subsequent agent.

    • Step Therapy may require trial of preferred drugs before covering alternatives.
    • If requesting an exception to ST, prescribers must explain medical reasons supporting the exception.
    Step Therapy

    Apply 'Step Therapy for New Starts Only' when ST is indicated

    Step Therapy applies to some drugs and is noted as 'Step Therapy for New Starts Only' in the key; for new starts follow the ST designation or request an exception if clinically justified.

    • ST flags in the table indicate step‑edit requirements for new starts.
    • Providers should consult the introduction pages for step‑therapy definitions and processes.
    Step Therapy

    Comply with 'ST NSO' step therapy requirements or request exception

    Products designated 'ST NSO' require step therapy as noted; prescribers must follow the step requirements or submit documentation explaining why the step cannot be met.

    • Examples of ST NSO entries include ZONISADE suspension and certain EXXUA/EXXUA packs.
    • If seeking an exception, provide clinical justification for bypassing step therapy.
    Note

    Refer to introduction/PA criteria for full Step Therapy rules

    Step therapy flags ('ST' shorthand) appear for select items but full step sequences are not detailed in this extract; providers must refer to the formulary introduction or PA criteria for specific step requirements.

    • FETZIMA is an example with QL and ST NSO entries.
    • Introduction pages contain definitions and processes for ST flags.
    Step Therapy

    Satisfy ST or request exception for products flagged ST / ST NSO

    Products marked 'ST' or 'ST NSO' (for example RYTARY, FANAPT titration packs) require step therapy per the formulary; providers must ensure step requirements are satisfied or request an exception.

    • FANAPT titration packs are marked ST NSO with specific QLs.
    • RYTARY is listed with ST — document prior therapies when submitting PA or exception requests.
    Note

    No explicit step‑therapy sequences in extract — consult detailed criteria

    This extract does not include explicit step‑therapy sequences (fail‑first chains); when ST is indicated, consult the plan’s detailed criteria or introduction pages for exact prior therapy requirements.

    • No complete fail‑first sequences are shown in these chunks.
    • Use the plan’s online documents or PA criteria for step sequence details.
    Step Therapy

    Address ST for diclofenac sodium gel 3% or request exception

    Some formulary entries (e.g., diclofenac sodium gel 3%) are flagged 'ST'; providers must meet the step‑therapy condition or submit clinical justification to override it.

    • Diclofenac sodium gel 3% has QL(300 GM per 30 days) and ST.
    • Document prior use of required agents or request an exception with supporting rationale.
    Step Therapy

    Satisfy ST or document exception for RELISTOR (ST‑flagged agents)

    RELISTOR INJECTION and certain other agents are marked 'ST'; ensure step‑therapy requirements are satisfied or include rationale for exceptions in the PA request.

    • RELISTOR INJECTION 8MG/0.4ML has QL(12 ML per 30 days) and ST.
    • Specify prior therapies and clinical response when requesting coverage beyond the step.
    Note

    Consult plan resources for full Step Therapy details when ST is shown

    No complete step‑therapy requirements are specified in this extract; when ST appears on a drug row, consult the formulary intro or the payer’s PA/step‑therapy documentation for details.

    • The extract shows ST flags but not full step sequences.
    • Contact the plan or refer to online PA/ST documents for exact requirements.
    Note

    Adhere to manufacturer‑labeled product limitations or request exception

    Some products are limited to specific manufacturer‑labeled items (e.g., 'Boehringer Ingelheim labeled products only'); when present, prescribe and document the exact labeled product or request an exception.

    • Entries may restrict coverage to manufacturer‑labeled starter packs or branded labeled products.
    • Examples include Boehringer Ingelheim labeled listings and AbbVie/HUMIRA labeled products.
    Documentation Required

    Provide medical justification for exception requests (72h standard; 24h expedited)

    When requesting an exception to PA, QL, or ST, the prescriber must explain the medical reasons supporting the exception; standard decisions are made within 72 hours and expedited decisions within 24 hours when appropriate.

    • Prescribers must provide clinical justification for exceptions.
    • Decision timelines: standard 72 hours; expedited 24 hours if request qualifies.
    Documentation Required

    Include required documentation for PA, QL, NDS and ST per Requirements/Limits

    Prescriptions subject to PA, QL, NDS, or ST must include documentation required by the Requirements/Limits field; include indication, prior therapies, and requested quantity/timeframe to support the request.

    • The Requirements/Limits field (PA, QL, ST, NDS) documents needed controls and supporting evidence.
    • Provide dose, duration, prior treatment history and rationale in PA or exception submissions.
    Billing Rule

    Adhere to Quantity Limits or document justification in PA/exception requests

    When a drug has a quantity limit (QL), prescribers/pharmacies must adhere to the stated QL or include documentation supporting the need for a larger quantity when requesting PA or an exception.

    • Examples of QLs: clonazepam ODT QL(300 EA per 30 days); ELIQUIS SOLUBLE QL(560 EA per 28 days); many specialty injectables list ML or EA limits.
    • Exceeding QL without an approved exception may result in denial.
    Prior Authorization

    Submit PA referencing the exact formulation and Requirements/Limits

    PA flags in the table imply that prior authorization is required and that prescribers must submit authorization requests referencing the specific formulation and QL shown.

    • Many entries show 'PA' or 'PA NSO' next to exact formulations — PA must reference those formulations.
    • Check the Requirements/Limits field for any QL values to include in the request.
    Documentation Required

    Provide PA/QL documentation per the formulary flags and introduction

    Table flags such as 'PA NSO' and explicit QL(...) indicate documentation and authorization requirements; providers should follow the payer’s prior authorization process and include supporting clinical information.

    • PA NSO denotes PA required as indicated; QL entries specify allowed units per time period.
    • Introduction pages explain the symbols and the PA submission process.
    Documentation Required

    Submit PA documentation for PA‑marked drugs (examples: GENOTROPIN, INCRELEX, ISTURISA)

    Prescribers must supply prior authorization documentation for drugs marked 'PA' (for example GENOTROPIN, INCRELEX, ISTURISA) to the plan’s PA process to obtain coverage.

    • ISTURISA requires QL(240 EA per 30 days for 1mg; 360 EA per 30 days for 5mg) plus PA.
    • Include indication, dosing schedule and clinical rationale with PA submission.
    Denial Risk

    Denial risk if PA/QL/NDS/ST requirements are not met

    Failure to obtain required prior authorization, exceeding stated quantity limits, or ignoring NDS/ST flags may result in claim denial — verify flags on the formulary entry before dispensing.

    • Denial triggers include lack of PA, exceeding QL, or attempting NDS when extended supply rules apply.
    • Claims for PA‑marked products may be denied without approved authorization.
    Denial Risk

    Avoid denials by securing PA for PA/PA NSO drugs and adhering to QLs

    Lack of required PA or exceeding QL are primary denial triggers; when a drug is labeled 'PA NSO' or 'PA' ensure PA is obtained to minimize denial risk.

    • PA NSO and PA flags indicate authorization is required; claims may be denied without it.
    • Exceeding quantity limits listed in QL(...) can also trigger denials.
    Denial Risk

    High denial risk for specialty/biologic injectables without PA

    Claims for many specialty products (including biologics and high‑cost injectables) may be denied if prior authorization is not obtained; check each product’s Requirements/Limits before prescribing.

    • High‑cost injections such as ORENCIA 250mg, FORTEO and teriparatide are listed with PA.
    • Biologics like ENBREL and HUMIRA require PA and often have QLs or manufacturer‑label restrictions.
    Note

    Refer to introduction pages for symbol definitions and PA/ST instructions

    Providers should reference the formulary introduction pages for definitions of symbols/abbreviations (PA, QL, ST, NDS, B/D) and for instructions on PA and step‑therapy processes.

    • Introduction pages provide symbol meanings and where to find PA/ST documentation.
    • Formulary ID and version (Formulary ID: 26218, Version: 12) are listed on the introduction pages.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy Criteria / Selected Agents

    Migraine/CGRP agents (formulary flags)

    Migraine/CGRP and acute migraine agents are covered subject to the following utilization controls as shown in the formulary:

    CGRP preventive therapies: AIMOVIG injection: QL(1 ML per 28 days) for 140 mg strength; PA required. AIMOVIG injection 70 mg: QL(2 ML per 28 days); PA required.QL as listed

    Per formulary Requirements/Limits: AIMOVIG entries include both QL and PA.

    Alternative CGRP agents: EMGALITY injection 120 mg: QL(2 ML per 28 days); PA required. EMGALITY injection 100 mg: QL(3 ML per 28 days); PA required.QL as listed

    Per formulary Requirements/Limits entries for EMGALITY.

    Acute migraine agents: NURTEC (rimegepant) tablet disintegrating 75 mg: QL(18 EA per 30 days); PA required. QULIPTA tablet (10/30/60 mg): Requirements/Limits noted in formulary (see table).QL as listed

    Per formulary Requirements/Limits: NURTEC shown with QL and PA; QULIPTA entry present in the migraine section.

    Step Therapy Rules

    SummarySource evidence
    Members may be required to try preferred drugs first (step therapy) before the plan will cover an alternative drug for the same condition.
    Formulary introduction explains step therapy may require trying specified alternative drugs first; see 'Are there any restrictions on my coverage?' and the Requirements/Limits Key defining ST.
    RuleSource evidence
    Step Therapy for New Starts Only applies where ST is indicated on the drug list.
    Legend entries include 'Step Therapy for New Starts Only' in the introduction/key indicating the ST designation applies to new starts as noted in the Requirements/Limits Key.
    Example product(s) marked ST NSOSource evidence
    ZONISADE suspension 100 mg/5 mL — Requirements/Limits = ST NSO.
    Multiple antidepressant/titration pack examples (e.g., EXXUA, FANAPT titration packs) show ST NSO or ST alongside quantity limits in the Requirements/Limits Key.
    ObservationSource evidence
    Some entries include the shorthand 'ST' or 'ST NSO' (e.g., FETZIMA shows 'ST NSO') but the full step-therapy sequencing rules are not provided in this extract.
    Formulary pages instruct providers to consult introduction pages for symbol definitions and detailed program rules; full step-edit rules are in the introduction rather than the excerpted table.
    FindingSource evidence
    No explicit step therapy sequences are listed in the extracted tables; many agents are annotated with 'PA NSO' or other flags instead.
    The extract contains numerous PA NSO annotations and quantity limits but does not contain detailed step-therapy failure/step sequencing criteria.
    ImplicationSource evidence
    Products flagged 'ST' or 'ST NSO' require step therapy per the formulary table; specific step details must be referenced in the plan's introduction or prior authorization criteria.
    Examples in the Requirements/Limits Key show multiple products annotated with ST or ST NSO indicating step-edit applies and must be met prior to coverage.
    Products with PA flags (diabetes/specialty)Source evidence
    MOUNJARO injection (various strengths) — Requirements/Limits = QL(2 ML per 28 days); PA.
    OZEMPIC injection (various sizes) and RYBELSUS tablet — listed with quantity limits and PA in the Requirements/Limits Key.
    Products requiring PASource evidence
    Multiple high-tier specialty injectables and supportive oncology/hematology agents are listed with 'PA' (examples: NEULASTA, PROCRIT/RETACRIT, eltrombopag, ENBREL entries).
    Requirements/Limits Key entries show PA required for many listed specialty products and injections; absence of PA may result in denial.
    SummarySource evidence
    Some specialty injectables and oral specialty drugs are subject to prior authorization (PA) and quantity limits (QL); the extract does not provide an explicit step sequence for these agents.
    Examples (PRALUENT, REPATHA, AUSTEDO XR, COBENFY starter packs) list QLs and PA in the Requirements/Limits Key but no step-therapy order is shown in the excerpt.
    ProductSource evidence
    diclofenac sodium gel 3% — Requirements/Limits = QL(300 GM per 30 days); ST.
    ProductSource evidence
    RELISTOR tablet 150 mg — Requirements/Limits = QL(90 EA per 30 days); ST.
    ProductsSource evidence
    GENOTROPIN Miniquick and GENOTROPIN injection formulations — Requirements/Limits = PA.
    ISTURISA tablets (1 mg and 5 mg) — Requirements/Limits = QL(240 EA per 30 days) / QL(360 EA per 30 days); PA.
    Adalimumab / biologic listing notesSource evidence
    Multiple adalimumab (HUMIRA) starter packs and pens are listed with quantity limits and PA; some starter/pack entries reference manufacturer-labeled products only.
    Formulary entries for HUMIRA include QL values and PA; select HUMIRA entries note 'Abbvie labeled products only'.
    AbbVie-labeled restriction examplesSource evidence
    HUMIRA pen and injection entries include 'Abbvie labeled products only' on certain formulations (e.g., HUMIRA PEN INJECTION 80 mg/0.8 mL and 40 mg/0.8 mL entries).
    Other biologic listings may include manufacturer-labeled restrictions (e.g., Boehringer Ingelheim labeled products only noted elsewhere in the table).

    Quantity Limits (QL) — Per-Product Examples

    inv-124: Cablivi example — 30 tablets per 30 days
    Cablivi example QLQL(30 EA per 30 days) — 30 tablets per 30 days
    Associated PACablivi entry also may include PA annotation in Requirements/Limits for injectables/complex agents
    Source contextCABLIVI INJECTION 11MG listed with QL(30 EA per 30 days) in the Hemostasis Agents section
    inv-125: JOURNAVX TABLET 50MG — QL(30 EA per 90 days)
    JOURNAVX QLQL(30 EA per 90 days)
    Therapeutic classListed under Analgesics with the 90‑day QL format
    InterpretationIndicates 30 each allowed in any 90‑day period
    inv-126: celecoxib capsule — QL(60 EA per 30 days)
    Celecoxib QLQL(60 EA per 30 days)
    Strengths coveredApplies to multiple strengths (100mg, 200mg, 400mg, 50mg) as listed
    TieringListed under NSAIDs/Nonsteroidal Anti-inflammatory Drugs section
    inv-127: diclofenac sodium gel 1% — QL(1000 GM per 30 days)
    Diclofenac gel QLQL(1000 GM per 30 days)
    Formulation noteExpressed in grams for topical gel preparations
    Related entryDiclofenac gel 3% elsewhere shows QL(300 GM per 30 days) dependent on concentration
    inv-128: buprenorphine patch weekly — QL(4 EA per 28 days)
    Buprenorphine patch QLQL(4 EA per 28 days)
    Patch strengths coveredWeekly patch formulations (various mcg/hr strengths) are limited to 4 per 28 days
    NDS noteSome patch entries include NDS indicating non-extended day supply rules may apply
    inv-129: clonazepam ODT 2mg — QL(300 EA per 30 days)
    Clonazepam ODT 2mg QLQL(300 EA per 30 days)
    Clonazepam ODT 0.125-1mg QLQL(90 EA per 30 days)
    Multiple formulationsTablet and ODT strengths show consistent EA-per-30-day limits across entries
    inv-130: clonazepam ODT 0.125-1mg — QL(90 EA per 30 days)
    Clonazepam lower-strength QLQL(90 EA per 30 days)
    Applies to ODT 0.125mg–1mg and corresponding tablet strengths
    ReferenceSee Requirements/Limits Key for anticonvulsant section
    inv-131: gabapentin capsule 400mg — QL(270 EA per 30 days)
    Gabapentin 400mg QLQL(270 EA per 30 days)
    Higher and lower strengthsOther gabapentin forms have different QLs (e.g., 360 EA, 150 EA, 180 EA depending on formulation)
    Liquid formulation noteSolution expressed in ML limits (e.g., QL(2160 ML per 30 days))

    Site of Care / Dispensing Rules

    Note

    Definitions and Abbreviations

    Background

    This document is the BlueCross Total Value Medicare Part D formulary (Drug List). It identifies covered drugs, their assigned drug tiers, and utilization controls such as Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST). For interpretive guidance (symbols/abbreviations) and fallback references relevant to Medicare Part D, providers should consult the formulary introduction pages referenced in the document.

    Biosimilar Substitution

    Note